Back to search results

Muscle and Movement With Anti-Obesity Medications

This study is looking at how exercise affects body changes in people taking new anti-obesity medications like semaglutide and tirzepatide. Researchers want to see if adding aerobic (like brisk walking) or resistance (like lifting weights) exercise to standard medical care makes a difference in body composition (fat, muscle, bone) and overall weight. The study aims to understand if exercise can provide extra health benefits while you're on these medications. They will measure your lean body mass (muscle and bone) at the beginning and after 6 months to see the results. The study is open to adults aged 18 to under 60 who are newly prescribed these medications for obesity.

Study design
This interventional study plans to enroll 40 participants. It will compare standard medical care to groups that also do supervised aerobic or resistance exercise.
What's involved
Participants will receive standard medical care, and some will also have supervised exercise sessions three times a week for 6 months. There will be check-ins with research staff at weeks 6, 12, and 18, plus a nutrition counseling session.
Compensation
Not stated in the trial record.
Follow-up
Your lean body mass will be measured at the start of the study and again after 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06645470

Muscle and Movement With Anti-Obesity Medications

Recruiting
NAAges 18+InterventionalTreatment
University of Kansas Medical Center
~40 participants
Updated 2026-05-11 on ClinicalTrials.gov
What's tested:Standard Medical Care (SMC)Monitoring ContactsAerobic TrainingResistance TrainingNutrition Education

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Lean Body Mass
Measured over 0 and 6 months

Conditions

Obesity and Overweight

Explore related trials

ObesityOverweight

Where it's being run

1 sites across 1 states
Kansas1

Study leadership

  • Renee J. Rogers, Ph.D. · PRINCIPAL_INVESTIGATOR · University of Kansas Medical Center

Who to contact

Renee J. Rogers, Ph.D.
[email protected]
913-588-8580
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Both males and females of all race/ethnic groups are eligible for participation in this study.
Age: Randomized Study: Adults that are 18 to \<60 years of age. Observational Study: Adults that are \>60 years of age.
Newly prescribed AOM (semaglutide, tirzepatide) for the treatment of obesity, approval for treatment (pharmacy, insurance, etc.), and the participant agreeing to start this treatment and continue treatment for at least 6 months (the participant will be recruited prior to this medication being initiated).
Body mass index (BMI) of \>27.0 kg/m2 with at least one weight-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) provided it this does not compromise the ability to safely complete the screening or outcome measures or to engage in the prescribed exercise interventions), or \>30 kg/m2 without weight-related complications. Enrollment will not be limited based on an upper BMI level provided that the participant meets the other eligibility requirements. However, weight or size limits of the dual-energy x-ray absorptiometry (DXA) system that is used to assess body composition must not be exceeded.
Ability to provide informed consent prior to participation in this study.
Clearance from the study physician for meeting all eligibility criteria for this study.

Exclusion

Type 2 diabetes.
Report moderate-to-vigorous exercise for \>60 min/week, and \>1 day of structured cardiovascular or resistance exercise over the past 3 months.
Report sustained weight loss of \>3% in the past 3 months.
History of metabolic/bariatric surgery.
Females who are pregnant, pregnant within the past 6 months, or reporting a planned pregnancy during the study period.
Report a current medical condition or treatment for a medical condition that could affect body weight or contradict engagement in any aspect of the outcome measures or interventions.
History of muscle conditions that may impact the quality of muscle or response to the study interventions (e.g., myopathy, muscular dystrophy, rhabdomyolysis, etc.).
Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction or history of cardiomyopathy, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).
Resting systolic blood pressure of \>160 mmHg or resting diastolic blood pressure of \>100 mmHg. If medicated for blood pressure control, the medication dose needs to be stable for \>6 months.
Eating disorders that would contraindicate weight loss or physical activity.
Alcohol or substance abuse.
Current psychological condition that is untreated, hospitalization for a psychological condition within the past 12 months, or not being on a stable dose of treatment for at least 6 months.
Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance at scheduled intervention sessions or assessments.

What this trial measures

  • Lean Body Mass0 and 6 months

    Lean body mass (kg) will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).